Amalgamated Bank Sells 625 Shares of Artivion, Inc. (NYSE:AORT)

Amalgamated Bank lowered its stake in shares of Artivion, Inc. (NYSE:AORT) by 5.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,248 shares of the company’s stock after selling 625 shares during the quarter. Amalgamated Bank’s holdings in Artivion were worth $299,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its position in shares of Artivion by 291.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after acquiring an additional 4,154 shares during the period. BNP Paribas Financial Markets grew its holdings in Artivion by 79.3% during the first quarter. BNP Paribas Financial Markets now owns 19,706 shares of the company’s stock valued at $417,000 after purchasing an additional 8,715 shares during the period. Russell Investments Group Ltd. increased its position in Artivion by 26.9% in the first quarter. Russell Investments Group Ltd. now owns 15,187 shares of the company’s stock worth $321,000 after buying an additional 3,217 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Artivion by 70.5% in the first quarter. State Board of Administration of Florida Retirement System now owns 19,197 shares of the company’s stock valued at $406,000 after buying an additional 7,940 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after buying an additional 33,982 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insider Buying and Selling at Artivion

In related news, SVP Jean F. Holloway sold 3,167 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.55, for a total value of $84,083.85. Following the sale, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. This trade represents a 1.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the sale, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. The trade was a 8.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on AORT. JMP Securities started coverage on shares of Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price objective on the stock. Stifel Nicolaus upped their price target on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Artivion in a research note on Friday, September 27th. Finally, Oppenheimer increased their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has an average rating of “Buy” and an average price target of $31.00.

Artivion Price Performance

Shares of NYSE:AORT opened at $26.65 on Monday. The company has a 50 day moving average of $26.34 and a 200 day moving average of $25.40. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a market cap of $1.12 billion, a P/E ratio of -1,332.50 and a beta of 1.75. Artivion, Inc. has a 12 month low of $13.42 and a 12 month high of $30.00.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.